Related Experiment Videos
Bone marrow stromal cells as targets for gene therapy
An Van Damme1, Thierry Vanden Driessche, Desire Collen
1Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology-University of Leuven, 49 Herestraat B-3000 Leuven, Belgium.
Current Gene Therapy
|July 12, 2002
Summary
Bone marrow stromal cells, including mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs), are key targets for cell and gene therapy. These cells can be engineered to treat various genetic disorders and diseases.
Area of Science:
- Stem cell biology
- Regenerative medicine
- Cell therapy
Background:
- Bone marrow comprises hematopoietic and adherent stromal cells.
- Adherent stromal cells include mesenchymal stem cells (MSCs) and differentiated stromal cells.
- A primitive stem cell, multipotent adult progenitor cell (MAPC), co-purifies with MSCs.
Purpose of the Study:
- To highlight the therapeutic potential of bone marrow stromal cells, MSCs, and MAPCs.
- To explore their role in cell and gene therapy applications.
- To discuss their capacity for protein secretion for treating genetic disorders.
Main Methods:
- Characterization of bone marrow stromal cell compartments.
- Identification and differentiation potential of MSCs and MAPCs.
- Engineering of stromal cells for therapeutic protein secretion.
Main Results:
- MSCs self-renew and differentiate into multiple lineages.
- MAPCs differentiate into MSCs, endothelial, epithelial, and hematopoietic cells.
- BM stromal cells offer potential for treating genetic diseases and tissue disorders.
Conclusions:
- Bone marrow stromal cells, MSCs, and MAPCs are promising candidates for cell and gene therapy.
- Engineering these cells can lead to novel treatments for protein deficiencies and other diseases.
- Further research into BM stromal cell potential can advance regenerative medicine.